Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from TrivarX Limited ( (AU:TRI) ).
TrivarX Limited has commenced a clinical trial to screen for major depressive episodes in veterans using its single-lead ECG technology. The trial, conducted in collaboration with the Greater Los Angeles Veterans Research and Education Foundation and the VA Greater Los Angeles Healthcare System, aims to validate the accuracy of TrivarX’s algorithm against established clinical standards. This initiative not only marks a significant milestone for TrivarX but also paves the way for future commercialization opportunities, potentially enhancing the company’s position in the mental health technology sector.
More about TrivarX Limited
TrivarX Limited is a mental health technology company that focuses on the early detection and screening of mental health conditions using objective measures. Founded in Australia, the company has offices in Perth and Minneapolis and is listed on the Australian Securities Exchange and the OTCQB Venture Market.
Average Trading Volume: 1,304,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.58M
See more data about TRI stock on TipRanks’ Stock Analysis page.